<?xml version="1.0" encoding="UTF-8"?>
<p>Other anti-influenza medications licensed for treatment, aside from oseltamivir and zanamivir, consist of an intravenous neuraminidase inhibitor, peravamir, and a novel oral inhibitor of cap-dependent endonuclease, baloxavir. Neuraminidase inhibitors are effective against both influenza A and B, while an additional class of antivirals that are no longer recommended for treatment of influenza due to reduced efficacy, neurological side effects, and widespread resistance, adamantanes (M2 inhibitors, amantadine and rimantadine), are only active against influenza A [
 <xref rid="r31" ref-type="bibr">31</xref>]. Although many patients with influenza exhibit minimal clinical improvement upon treatment with these medications, they are currently recommended for treatment of all hospitalised patients, even prior to laboratory confirmation of influenza infection. Evidence shows that the greatest benefit is seen when these drugs are administered 24-30 hours prior to symptom onset, in which case they reduce symptom duration by 0.5-3 days and reduce transmission risk [
 <xref rid="r39" ref-type="bibr">39</xref>â€“
 <xref rid="r42" ref-type="bibr">42</xref>].
</p>
